GRAL
GRAIL Inc.
$45.63
-$1.93(-4.06%)
45
Overall
60
Value
40
Tech
36
Quality
Market Cap
$2.97B
Volume
945.92K
52W Range
$20.44 - $118.84
Target Price
$72.40
Company Overview
| Mkt Cap | $2.97B | Price | $45.63 |
| Volume | 945.92K | Change | -4.06% |
| P/E Ratio | -1.5 | Open | $46.72 |
| Revenue | $125.6M | Prev Close | $47.56 |
| Net Income | $-2.0B | 52W Range | $20.44 - $118.84 |
| Div Yield | N/A | Target | $72.40 |
| Overall | 45 | Value | 60 |
| Quality | 36 | Technical | 40 |
No chart data available
About GRAIL Inc.
GRAIL, Inc., a commercial-stage healthcare company, focuses on developing technologies for early cancer detection in the United States and internationally. It provides Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company offers development services including support for ongoing clinical studies, pilot testing, research, and therapy development. It also develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Latest News
Analysts’ Top Healthcare Picks: GRAIL Inc (GRAL), Bicycle Therapeutics (BCYC)
Howard Kim•23 days ago
Guggenheim Sticks to Their Buy Rating for GRAIL Inc (GRAL)
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
Canaccord Genuity Reaffirms Their Buy Rating on GRAIL Inc (GRAL)
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GRAL | $45.63 | -4.1% | 945.92K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |